| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030336400 |
| P356 | DOI | 10.1038/MODPATHOL.2012.87 |
| P698 | PubMed publication ID | 22627739 |
| P5875 | ResearchGate publication ID | 225043698 |
| P50 | author | Silvano Bosari | Q38544154 |
| Ivan Cortinovis | Q41117511 | ||
| Nicola Stefano Fracchiolla | Q49561823 | ||
| Agostino Cortelezzi | Q56461136 | ||
| Umberto Gianelli | Q57305785 | ||
| Anna Bossi | Q57442034 | ||
| Nicola S. Fracchiolla | Q58881114 | ||
| P2093 | author name string | Alessandra Iurlo | |
| Federica Savi | |||
| Giorgio Lambertenghi Deliliers | |||
| Alessia Moro | |||
| Claudia Vener | |||
| Tommaso Radice | |||
| Chiara De Philippis | |||
| Federica Grifoni | |||
| P2860 | cites work | Bone marrow biopsy morbidity and mortality: 2002 data | Q30970278 |
| Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines | Q33773400 | ||
| New approaches in the treatment of myelofibrosis | Q35964242 | ||
| Hematopathologic findings in chronic idiopathic myelofibrosis | Q36275880 | ||
| New insights into the pathogenesis and drug treatment of myelofibrosis | Q36385807 | ||
| Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution | Q36779588 | ||
| Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres | Q36957972 | ||
| Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis | Q40650130 | ||
| Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial | Q43641812 | ||
| Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes | Q44302357 | ||
| Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia | Q57589520 | ||
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 | ||
| Quantitation of Bone Marrow Reticulin—A Normal Range | Q71786528 | ||
| Myelofibrosis with myeloid metaplasia | Q73712758 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis | Q79924038 | ||
| Significance of bone marrow fibrosis in multiple myeloma | Q81334285 | ||
| Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system | Q82045907 | ||
| Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis | Q82299413 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1193-1202 | |
| P577 | publication date | 2012-05-25 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis | |
| P478 | volume | 25 |
| Q27342179 | A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis |
| Q50986633 | Anti-transforming growth factor-β therapy in patients with myelofibrosis. |
| Q45236578 | Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis |
| Q26744113 | Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies |
| Q53100468 | Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. |
| Q99730667 | CYTOGENETIC STUDY IN PRIMARY MYELOFIBROSIS AT DIAGNOSIS: CLINICAL AND HISTOLOGICAL ASSOCIATION AND IMPACT ON SURVIVAL ACCORDING TO WHO 2017 CLASSIFICATION IN AN ITALIAN MULTICENTER SERIES |
| Q48138032 | Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology |
| Q39255427 | Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. |
| Q38187675 | Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. |
| Q47284112 | Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. |
| Q36050183 | Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis |
| Q37035925 | Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. |
| Q88005433 | Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification |
| Q38689790 | European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. |
| Q54357496 | High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. |
| Q89587063 | Histological evaluation of myeloproliferative neoplasms |
| Q92270548 | Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach |
| Q51733623 | Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. |
| Q28073296 | Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors |
| Q37548944 | Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes |
| Q38683559 | Myeloproliferative neoplasms: Morphology and clinical practice |
| Q26750696 | Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib |
| Q57786924 | Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report |
| Q33442613 | Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |
| Q58592871 | Prefibrotic myelofibrosis: treatment algorithm 2018 |
| Q33438592 | Primary autoimmune myelofibrosis with severe thrombocytopenia mimicking immune thrombocytopenia: A case report |
| Q52862082 | Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. |
| Q38087202 | Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia |
| Q33432755 | Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. |
| Q33443649 | Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients |
| Q45892294 | Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms |
| Q38823803 | Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis |
| Q33417217 | Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms |
| Q48144615 | Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis |
| Q38845307 | Survival analysis, more than meets the eye. |
| Q33443246 | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
| Q33407572 | The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes |
| Q53084678 | The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. |
| Q48106053 | The role of extracellular matrix stiffness in megakaryocyte and platelet development and function. |
| Q42327796 | The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm. |
| Q40126127 | Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. |
| Q38378710 | Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms |
| Q54285700 | Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. |
| Q35705470 | WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience |
| Q38154519 | WHO classification of myeloproliferative neoplasms (MPN): A critical update |
Search more.